Which site is frequently recommended for administering heparin injections
Iran University of Medical Sciences, Department of Biostatistics, School of Public Health, Hemmat Highway, TehranIran, 0098 Show
Find articles by Leila Janani Ali Akbari SariTehran University of Medical Sciences, Department of Health Management and Economics, School of Public Health, Poorsina St, TehranIran, 1653867944 Find articles by Ali Akbari Sari Disclaimer Isfahan (Khorasgan) Branch, Islamic Azad University, Department of Nursing, IsfahanIran, Iran University of Medical Sciences, Department of Biostatistics, School of Public Health, Hemmat Highway, TehranIran, 0098 Tehran University of Medical Sciences, Department of Health Management and Economics, School of Public Health, Poorsina St, TehranIran, 1653867944 Mina Mohammady, Email: [email protected], Email: [email protected]. Editorial Group: Cochrane Vascular Group. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This article is an update of "Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity" in volume 2017, CD008077. This article has been updated. "Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity" in volume 2021, CD008077. AbstractBackgroundHeparin is an anticoagulant medication that is usually injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma, and pain at the injection site. One of the factors that may affect pain, haematoma, and bruising is injection speed. For patients and healthcare providers, strategies that can reduce pain and bruising are considered important. Reducing patients' discomfort and concerns whenever and wherever possible is an important aim of nursing. Several studies have been carried out to see if speed of injection affects the amount of pain and bruising where the injection is given, but results of these studies have differed and study authors have not reached a clear final conclusion. This is the first update of the review first published in 2014. ObjectivesTo assess the effects of duration (speed) of subcutaneous heparin injection on pain, haematoma, and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Search methodsFor this update, the Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (last searched March 2017) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2). The CIS also searched trials registries for details of ongoing or unpublished studies. Review authors searched two Persian databases ‐ Iranmedex and Scientific Information Database (SID) ‐ as well as Google Scholar. Selection criteriaWe sought randomised controlled trials (RCTs) comparing the effects of different durations of subcutaneous injection of heparin on pain, bruising, and haematoma at the injection site. Data collection and analysisTwo review authors (MM, LJ), working independently, extracted data onto a structured form and assessed study quality. We used the criteria recommended by Cochrane to assess the risk of bias of included studies. For the outcomes, we calculated the mean difference (MD) or the standardised MD (SMD) with corresponding 95% confidence intervals (CIs). We pooled data using fixed‐effect and random‐effects models. We used GRADE to assess the overall quality of evidence supporting outcomes assessed in this review. Main resultsFor this update, we identified three new studies and therefore included in the Review four studies with a total of 459 participants who received subcutaneous injections of LMWH into the abdomen. Only one trial reported the injected drug volume (0.4 mL). Owing to the nature of the intervention, it was not possible to blind participants and care givers (personnel) in any included study. Two studies described blinding of outcome assessors; therefore overall, the methodological quality of included studies was moderate. The duration of the fast injection was 10 seconds and the duration of the slow injection was 30 seconds in all included studies. Three studies reported site pain intensity after each injection at different time points. Two studies assessed site pain intensity immediately after each injection, and meta‐analysis on 140 participants showed no clear difference in site pain intensity immediately post slow injection when compared to fast injection (low‐quality evidence; P = 0.15). In contrast, meta‐analysis of two studies with 59 participants showed that 48 hours after the heparin injection, slow injection was associated with less pain intensity compared to fast injection (low‐quality evidence; P = 0.007). One study (40 participants) reported pain intensity at 60 and 72 hours after injection. This study described no clear difference in site pain intensity at 60 and 72 hours post slow injection compared to fast injection. All four included studies assessed bruise size at 48 hours after each injection. Meta‐analysis on 459 participants showed no difference in bruise size after slow injection compared to fast injection (low‐quality evidence; P = 0.07). None of the included studies measured the incidence of haematoma as an outcome. Authors' conclusionsWe found four RCTs that evaluated the effect of subcutaneous heparin injection duration on pain intensity and bruise size. Owing to the small numbers of participants, we found insufficient evidence to determine any effect on pain intensity immediately after injection or at 60 and 72 hours post injection. However, slow injection may reduce site pain intensity 48 hours after injection (low‐quality evidence). We observed no clear difference in bruise size after slow injection compared to fast injection (low‐quality evidence). We judged this evidence to be of low quality owing to imprecision and inconsistency. Keywords: Humans, Middle Aged, Anticoagulants, Anticoagulants/administration & dosage, Anticoagulants/adverse effects, Contusions, Contusions/chemically induced, Contusions/prevention & control, Heparin, Heparin/administration & dosage, Heparin/adverse effects, Injections, Subcutaneous, Injections, Subcutaneous/adverse effects, Injections, Subcutaneous/methods, Pain, Pain/etiology, Pain/prevention & control, Randomized Controlled Trials as Topic, Time Factors Does the speed of injection make a difference in the amount of pain and bruising in people receiving heparin injections?Background Heparin is a drug that is used to help stop blood from clotting. It comes in two forms ‐ unfractionated heparin (UFH) and low molecular weight heparin (LMWH). These are usually given by injection just underneath the skin. Injected heparin goes into the layer of fat under the skin so that it is released slowly into the body. This type of injection can sometimes cause bruising and pain at the site where the needle goes in. It can sometimes result in a swelling that contains blood, called a haematoma. For patients and healthcare providers, strategies that can reduce pain and bruising are considered important. Reducing patients' discomfort and concerns whenever and wherever possible is an important aim of nursing. Several studies have been carried out to see if the speed of injection affects the amount of pain and bruising at the site where the injection is given, but their results differed and study authors did not reach a clear final conclusion. Study characteristics and key results We searched for studies that investigated the effects of speed of injection on the amount of pain and bruising where the injection is given (current to March 2017) and found four studies that fitted our review criteria. These studies took place in Turkey, Italy, and China. They enrolled a total of 459 people including 287 female and 172 male participants. All patients received LMWH, and none of the studies used UFH. Participants were treated in hospital, in neurology, orthopaedic, and cardiology units. Investigators injected heparin slow or fast into the abdomen (stomach) of participants. Participants could watch the injection being given and knew whether it was fast (10 seconds long) or slow (30 seconds long). Participants given injections said that pain was less with the slow injection after 48 hours. Owing to the small numbers of participants, we found insufficient evidence to determine any effect on pain intensity immediately after injection or at 60 hours and 72 hours after injection. The bruise was not smaller with the slow injection. None of the included studies reported if participants had a swelling with blood inside (haematoma). Quality of the evidence We graded the quality of evidence as low because we found only a small number of published studies that reported on this question. These studies were small and had contradictory results. The fact that participants knew whether they received a fast or a slow injection may have affected the results. Summary of findingsSummary of findings for the main comparisonSlow versus fast subcutaneous heparin injection for prevention of bruising and site pain intensity Slow vs fast subcutaneous heparin injection for prevention of bruising and site pain intensityPatient or population: patients treated with subcutaneous heparin injections Open in a separate window aWe downgraded the quality of evidence by two steps owing to study limitations, as we identified few studies with small numbers of participants (imprecision) and high heterogeneity (I2 = 73%) (inconsistency). bWe downgraded the quality of evidence by two steps owing to study limitations, as we identified few studies with small numbers of participants (imprecision) and high heterogeneity (I2 = 72%) (inconsistency). cWe downgraded the quality of evidence by two steps owing to study limitations, as we identified few studies with small numbers of participants (imprecision) and high heterogeneity (I2 = 85%) across studies (inconsistency). BackgroundDescription of the conditionHeparin is an anticoagulant medication that is used to prevent further development of an existing thrombus or new clot formation. Heparin is prescribed for treatment or prevention of thromboembolic disorders. Different forms of heparin are available. Unfractionated heparin (UFH) may be administered by subcutaneous (SC) or intravenous (IV) injection, but low molecular weight heparin (LMWH) is administered only subcutaneously (). Description of the interventionSubcutaneous administration of heparin is frequently carried out as a nursing intervention (). Subcutaneous injection is normally chosen when slow and continuous absorption of a drug (e.g. insulin, heparin) is needed. The drug is injected into fat and connective tissue underlying the dermis, where less blood flow results in a slower absorption rate. Suitable sites for subcutaneous injections are often the umbilical region of the abdomen and the lateral sides of the arms and thighs (). Administration and injection techniques that are used for subcutaneous heparin injection may cause adverse outcomes such as bruising, haematoma, and pain at the injection site (; ). The incidence of bruising at the injection site when 3‐mL and 1‐mL syringes are used has been reported as 69% and 79%, respectively (). How the intervention might workAdverse drug reactions are a relatively common problem that might cause harm to patients. Nurses should apply techniques that minimise the side effects of subcutaneous injections, including site pain, haematoma, and bruising. It can be argued that slow versus fast injection of heparin might significantly reduce pain, haematoma, and bruising at the injection site. However, a systematic review has not been conducted to explore this theory. Slow administration of heparin allows time for subcutaneous tissue to accommodate the injected volume, resulting in reduced pressure, capillary bleeding, and site pain, and minimising the likelihood of other damage (). Why it is important to do this reviewSome patients receive subcutaneous heparin for a long time from the time of hospital admission until after hospital discharge (). With daily heparin injections for several weeks, the risk of extensive bruising in addition to pain at the injection site is high. Therefore, for patients and healthcare providers, strategies that can reduce pain and bruising are considered important. Reducing patients' discomfort and concerns whenever and wherever possible is an important aim of nursing. Several studies have explored the effects of factors such as temperature, syringe size, needle gauge, injection volume, and air bubble in the syringe on the incidence of bruising, haematoma, and pain at the injection site (; ; ; ). Other studies have explored the effect of duration of the injection on the incidence of bruising and pain (; ; ). Some investigators have recommended that subcutaneous heparin injections must be given slowly to reduce bruising and pain, but others have reported no significant differences between the two techniques in terms of bruising and pain (; ; ; ). Several studies have compared slow versus fast subcutaneous injection of heparin, but researchers have reported variable results and study authors were not able to reach a clear final conclusion about the exact speed of heparin injection (; ; ). This controversy highlights the importance of conducting a systematic review to explore the effect of different durations of heparin injection on complications at the injection site. ObjectivesTo assess the effects of duration (speed) of subcutaneous heparin injection on pain, haematoma, and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin (UFH) or low molecular weight heparin (LMWH). MethodsCriteria for considering studies for this reviewTypes of studiesWe searched for randomised controlled trials (RCTs) that we could include in this review. We excluded clinical controlled trials (CCTs), quasi‐randomised controlled trials (QRCTs), and quasi‐experimental studies. Types of participantsWe included studies in which participants were males and females 18 years of age or older who were admitted to hospitals or clinics and treated with subcutaneous injections of heparin including LMWH and UFH. We excluded trials involving people treated with other anticoagulant drugs. Types of interventionsWe included studies in which the intervention consisted of slow subcutaneous administration of heparin (LMWH or UFH) compared to fast subcutaneous administration of heparin. We considered an injection speed of 20 or more seconds as a slow injection, and an injection speed of less than 20 seconds as a fast injection. Types of outcome measuresPrimary outcomes
Secondary outcomes
Search methods for identification of studiesWe did not restrict language of publication. Electronic searchesFor this update, the Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials.
See for details of the search strategy used to search CENTRAL. The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Allied and Complementary Medicine Database (AMED), and through handsearching of relevant journals. The full list of databases, journals, and conference proceedings that have been searched, as well as the search strategies used, is presented in the Specialised Register section of the Cochrane Vascular Module in the Cochrane Library (Specialised Register; www.cochranelibrary.com). The CIS also searched the following trials registries for details of ongoing and unpublished studies.
See for details of trial registries searches. In addition, review authors searched Google Scholar (November 2016) and updated the search of two Persian databases ‐ Iranmedex (November 2016) and the Scientific Information Database (SID) (November 2016) ‐ using the search strategies provided in and (http://health.barakatkns.com/irmedex/index.asp; http://www.sid.ir/En/index.asp). Searching other resourcesFor this update, we reviewed the reference lists of included studies to identify other studies for inclusion. We also tried to contact relevant trial authors to identify additional studies. Data collection and analysisSelection of studiesTwo review authors (MM, LJ) independently assessed titles and abstracts of the studies retrieved by searching to determine whether each study met the inclusion criteria. If it was not possible to include or exclude a study on the basis of the title or abstract, review authors obtained the full version of the article. The same two review authors (MM, LJ) then assessed the full papers independently to explore if they met the inclusion criteria. We resolved disagreements by discussion and, if necessary, by consultation with the third review author (AAS). Data extraction and managementTwo review authors (MM, LJ) independently extracted data from the included studies using a structured data extraction form. We resolved disagreements by discussion and, if necessary, by consultation with the third review author (AAS). We collected the following data from the included studies: study design; method of randomisation; method of concealment of allocation; blinding, details of participants, details of interventions, and duration of interventions; main inclusion and exclusion criteria; outcomes; methods of measuring pain, bruising, and haematoma; and methods of performing statistical analysis and reporting results. Assessment of risk of bias in included studiesTwo review authors (MM, LJ) independently assessed the risk of bias of included studies. We resolved disagreements by discussion and, if necessary, by consultation with the third review author (AAS). We used the Cochrane 'Risk of bias' tool as described by Higgins when assessing risk of bias (). Measures of treatment effectBruise size and pain intensity were continuous outcome measures. Therefore, we calculated the mean difference (MD) and 95% confidence intervals (95% CIs) for these outcomes. As investigators measured bruise size using different scales, we calculated the standardised mean difference (SMD) and 95% CIs to pool data. Unit of analysis issuesCross‐over trials were eligible for inclusion in this review because heparin has a temporary effect and the half‐life of heparin is 4.5 to 7 hours after administration. Therefore, the first administration of heparin has no effect on formation of bruises at the second injection. We did not expect to find cluster‐randomised trials, and we identified none for inclusion in this review. The individual participant was the unit of analysis. Dealing with missing dataWe contacted trialists to ask them to provide missing information when needed. Assessment of heterogeneityWe visually inspected forest plots and determined the I2 and Chi2 statistics to evaluate heterogeneity among the included studies. Assessment of reporting biasesIt is recommended that the test for funnel plot asymmetry to detect publication bias should be used when at least 10 studies are included in the review (). We included only four studies and determined that it was not appropriate to prepare a funnel plot. Data synthesisWe summarised study outcomes using narrative and quantitative methods. We applied a fixed‐effect model for meta‐analyses unless heterogeneity was high (I2 > 40%), in which case we used a random‐effects model for data synthesis. We used MD or SMD to pool continuous outcomes. Subgroup analysis and investigation of heterogeneityFor this update, we subgrouped outcomes according to different measures used by trialists to recording bruise size (mm or mm2) and different time points of assessment. If sufficient studies are included, and if appropriate in future updates, we will perform subgroup analyses according to participants' sex, age, etc. Sensitivity analysisWe planned to perform a sensitivity analysis to assess possible influences of the following factors on effect size, if sufficient studies met the inclusion criteria of this review.
'Summary of findings'We created a 'Summary of findings' table using GRADEpro software to summarise the evidence derived when investigators compared fast subcutaneous heparin injections versus slow injections in patients requiring heparin () (Table 1). We included outcomes of pain intensity, bruise size, and extent of haematoma, as described under . We calculated assumed control intervention risks by using mean measurements in the control groups of selected studies for each outcome. We used the GRADE system to grade the quality of evidence as high, moderate, low, and very low, upon assessing within‐study risk of bias, inconsistency, directness of evidence, imprecision, and publication bias (). ResultsDescription of studiesSee and . Results of the searchSee Figure 1. Open in a separate window Figure 1 Study flow diagram. Included studiesFor this update, we identified three new studies (; ; ). This review includes four studies with a total of 459 participants that were conducted in Italy (Palese), Turkey (Sendir and Zaybak), and China (Zhao) (; ; ; ). Three studies were published in English (Palese, Sendir, and Zaybak) and one in Chinese (Zhao) (; ; ; ). Three studies were small, including from 19 to 100 participants. The largest study involved 300 participants (). Two trials included more females (Palese and Sendir), one included more males (Zhao), and one included equal numbers of males and females (Zaybak) (; ; ; ). All studies included participants who received subcutaneous injections of LMWH, and no studies included participants given UFH. All studies performed subcutaneous injections into the abdomen. Only one trial reported the injected drug volume (0.4 mL) (). The included studies enrolled participants who were hospitalised in orthopaedics units (Palese and Sendir); cardiology units (Zhao); and neurology, orthopaedics, and cardiology units (Zaybak) (; ; ; ). Sendir randomised participants to three groups: group A (injection duration 10 seconds), group B (injection duration 30 seconds and 5‐minute dry cold local application), and group C (injection duration 30 seconds) (). We did not consider results from the group with injection duration of 30 seconds that applied 5‐minute dry cold locally, as this was not an objective of the review (). Zhao divided participants into six groups. Four groups investigated the effects of different injection durations and different pressing time on the injection site (). We did not consider results from these four groups, as these were not the objectives of our review. We included as the control group the group that injected heparin for 10 seconds without pressing, and as the intervention group the group that injected heparin for 30 seconds without pressing (). Two studies used an applied self‐controlled design whereby every participant received the slow injection into one side of the abdomen (as intervention) and the fast injection into the other side of the abdomen (as control) (; ). Two other studies applied parallel design whereby investigators randomly allocated participants to different groups (; ). Only one trial reported the source of funding (). Details of all included studies are given in the table. Excluded studiesFor this update, we excluded seven additional studies (; ; ; ; ; ; ). In total, we excluded 21 studies. We excluded eight studies because they used a quasi‐randomised design (; ; ; ; ; ; ; ). We excluded three studies because they used a non‐randomised design (; ; ). We excluded two studies because investigators used other anticoagulant drugs during the study (; ). We excluded one study because researchers compared 10‐second heparin injection versus 30‐second heparin injection plus air lock (). We excluded another study because study authors compared 10‐second heparin injection versus 10‐second injection and waiting for 10 seconds before withdrawing the needle (). We excluded one study because heparin injection duration was less than 20 seconds in all comparison groups (). The remaining excluded studies compared various techniques of heparin injection but did not explore the effects of injection duration on study outcomes. Two of these studies compared two techniques (; ). One study compared three different techniques (). Two studies compared four techniques of heparin injection (; ). Details of the excluded studies are given in the table. Risk of bias in included studiesFor a summary of 'Risk of bias', see the table and Figure 2. Open in a separate window Figure 2 Risk of bias summary: review authors' judgements about each risk of bias item for each included study. AllocationTwo studies adequately described methods of random sequence generation (; ). One of these studies used a computerised randomisation programme to generate random sequence (). The other study used a table of random numbers (). However, methods of allocation concealment were unclear in these studies (; ). Two studies gave every participant a slow injection into one side of the abdomen and a fast injection into the other side of the abdomen (; ). Therefore, it was not possible to randomise participants into two separate groups. However, participants could instead be randomised into intervention or control groups according to treatment order. Each participant was given one of the two injection techniques (injection duration of 10 or 30 seconds) for the first injection and the second technique 12 hours later. For each individual, the technique to be used first (injection duration of 10 or 30 seconds) was identified randomly using a randomised sequence. Two studies did not describe the methods of sequence generation and allocation concealment used (; ). The CIS contacted the authors of the Palese study to request information about the randomisation method used, and they stated that the random sequence was generated by computer (). BlindingOwing to the nature of the intervention, it was not possible to blind participants and care givers in all included studies. Two studies described blinding of outcome assessors (; ). The Zaybak study was at unclear risk of detection bias because, although study authors mentioned assessor blinding, they provided no description of assessor blinding for bruising (). Sendir investigators reported that they used unblinded methods, leading to high risk of performance bias (). Incomplete outcome dataAll included studies provided an adequate description of individual study withdrawals and dropouts. Sendir and Zhao reported 6.25% and 10% dropouts in one group, respectively, with no described intention‐to‐treat analysis, so we assigned high risk of bias (; ). Selective reportingAlthough we did not have access to individual study protocols, study reports suggest that investigators reported all expected outcomes. Other potential sources of biasThree studies did not provide clear descriptions about some aspects of heparin injection (e.g. heparin temperature, syringe size, injection volume, air bubble in the syringe) (; ; ). These factors may have affected study outcomes, and so we judged these studies as being at unclear risk of other bias. Effects of interventionsSee: Table 1 Pain intensityThree studies evaluated site pain intensity at different time points after each injection. One study reported pain intensity immediately after injection and at 48, 60, and 72 hours after each injection (). Another reported pain intensity immediately after injection (). The third reported pain intensity at 48 hours after each injection (). The fourth study did not report injection pain intensity (). Heterogeneity was high for this outcome, so we pooled results of different studies using a random‐effects method. In addition, we pooled data according to different time points reported in included studies, so numbers of studies and of participants at each time point were small. Meta‐analysis of data from two trials showed no clear differences in site pain intensity immediately after slow injection compared to fast injection (mean difference (MD) ‐1.52, 95% confidence interval (CI) ‐3.56 to 0.53; participants = 140; I2 = 73%; P = 0.15; low‐quality evidence) (; ). See Analysis 1.1. Open in a separate window Analysis 1.1 Comparison 1 Slow versus fast heparin injections, Outcome 1 Intensity of injection pain. Meta‐analysis of data from two RCTs showed reduced site pain intensity 48 hours after slow injection compared to fast injection (MD ‐1.68, 95% CI ‐2.91 to ‐0.45; participants = 59; I2 = 72%; P = 0.007; low‐quality evidence) (; ). See Analysis 1.1. Only one study reported pain intensity at 60 and 72 hours after injection (). This study described no clear differences in site pain intensity at 60 hours post slow injection compared to fast injection (MD ‐1.00, 95% CI ‐2.15 to 0.15; participants = 40; I2 = 0%; P = 0.09); or at 72 hours post injection (MD ‐0.80, 95% CI ‐1.70 to 0.10; participants = 40; I2 = 0%; P = 0.08; low‐quality evidence). See Analysis 1.1. Size of bruiseTwo studies used millimetric measuring papers to measure the area of the bruise and recorded it as square millimetres (mm2) (; ). Two studies measured the largest diameter of the bruise and recorded it as millimetres (mm) (; ). We used the standardised mean difference (SMD) to pool data from these different outcome measures. All four studies reported bruise size 48 hours after injection. Heterogeneity was high for this outcome (I2= 85%), so we pooled results of different studies using the random‐effects method. We pooled data according to different time points reported in included studies, so the numbers of studies and of participants at each time point were small. Meta‐analysis revealed no difference in bruise size after slow injection compared to fast injection after 48 hours (SMD ‐0.60, 95% CI ‐1.24 to 0.04; participants = 459; studies = 4; P = 0.07) and detected no subgroup differences (P = 0.43). See Analysis 1.2. Open in a separate window Analysis 1.2 Comparison 1 Slow versus fast heparin injections, Outcome 2 Bruise size 48 hours after injection. Only one study assessed bruise size after 60 hours, showing no clear differences between intervention and control groups when these data were pooled (MD ‐3.85, 95% CI ‐8.99 to 1.29; participants = 40; P = 0.14; low‐quality evidence) (). See Analysis 1.3. Open in a separate window Analysis 1.3 Comparison 1 Slow versus fast heparin injections, Outcome 3 Bruise size. Two studies assessed bruise size after 72 hours (; ). Heterogeneity was low for this outcome (I2 = 38%), therefore we pooled results of these studies using a fixed‐effect method and found no clear difference between slow and fast injections of heparin (MD ‐2.29, 95% CI ‐6.57 to 1.99; participants = 140; P = 0.29). See Analysis 1.3. Incidence of haematomaNone of the included studies measured the incidence of haematoma as an outcome. DiscussionSummary of main resultsThis systematic review incorporated data from four trials enrolling 459 participants to assess the effects of duration of subcutaneous heparin injection on pain and bruise size at the injection site. Results of this review show that slow injection may reduce pain intensity after 48 hours compared to fast injection, but that this reduction may not be detected immediately, nor at 60 or 72 hours after injection (low‐quality evidence). Review results also show that the slow injection technique had no clear effect on bruise size compared to the fast injection technique (low‐quality evidence). None of the included studies measured haematoma incidence after injection. Overall completeness and applicability of evidenceAll studies included in this update injected heparin subcutaneously into the abdomen, but two excluded studies injected heparin into the arm (; ). Therefore, it should be considered that pain intensity and bruise size at the injection site could be different depending on whether heparin is injected into the arm, thigh, or abdomen. Similarily, all included studies used low molecular weight heparin (LMWH), and it is possible that outcomes could have been different had they used unfractionated heparin (UFH). To minimise any confounding effect, we excluded studies in which investigators also treated participants with antiplatelet or anticoagulant drugs because of the possible effects of these agents on bruising and haematoma size. Included studies provided no clear description of how analgesic medications were used. In addition, studies used different injection protocols such as needle gauge, syringe size, heparin volume injected, injection technique used, experience of the injector, etc, and did not clearly describe these. Therefore, it should be considered that these factors, along with injection speed, may also affect pain intensity and bruise size at the injection site. Quality of the evidenceSee Table 1. All studies included in this review were randomised controlled trials (RCTs), and we assessed the overall methodological quality of these studies as moderate, as the nature of the intervention made a double‐blind study design impossible. Two trials blinded outcome assessors (; ). We assessed the overall quality of evidence presented using the GRADE approach. We judged the body of evidence related to pain intensity and size of the bruise to be of low quality. We downgraded the quality of the evidence owing to study limitations, as we identified only a few studies with small numbers of participants. This may have affected the precision of results. Pooling of data from all included studies in the meta‐analyses was impossible, as some studies reported outcomes at different time points or used different measurements, thus reducing the numbers of available studies and participants for each outcome. One study addressed only bruise size (). The other studies addressed all primary outcomes. We detected heterogeneity across studies. Potential biases in the review processNone of the review authors was involved in any of the included or excluded trials. Furthermore, none of the review authors had any conflicts of interest. To minimise the possibility of bias, we tried to locate eligible RCTs by conducting a broad and comprehensive search of several national and international databases. However, it is still possible that we did not recognise all eligible studies. In addition, two trained review authors independently performed study selection, data collection, and quality assessment of included studies. We followed Cochrane processes as described by Higgins when assessing risk of bias (). Agreements and disagreements with other studies or reviewsA recent published systematic review evaluated the effects of heparin injection duration on injection pain intensity and bruising (). Some of the findings of the previous review were not in line with the findings of our review. Yi reported that slow heparin injection reduced pain intensity and bruise size at 48 and 60 hours after each injection (). The Yi review included three RCTs and five quasi‐experimental studies (). Our review did not include quasi‐experimental studies because of potential risk of bias due to inadequate allocation concealment, as this could lead to overestimation of treatment efficacy by 30% to 40% compared to trials with adequate allocation concealment (). Inclusion of quasi‐experimental studies could account for the difference between results of the two reviews. In addition, Yi and colleagues limited their search strategies to studies published only in Chinese and English, and our search strategies did not restrict the language of publication (). Although we identified only papers published in Chinese and English in the current version of our review, this may not be the case in future searches, and we believe our search strategy is more comprehensive. Authors' conclusionsSome patients receive subcutaneous heparin for a long time from hospital admission to after hospital discharge. With daily heparin injections for several weeks, the risk of extensive bruising in addition to pain at the injection site is high. Therefore, patients and healthcare providers consider strategies that can reduce pain and bruising to be important. For this reason, we sought to evaluate the effectiveness of subcutaneous heparin injection duration on pain intensity and bruise size and found four randomised controlled trials (RCTs). Owing to the small numbers of participants, evidence was insufficient for review authors to confirm an effect on pain intensity immediately after injection (low‐quality evidence) or at 60 and 72 hours post injection. However, slow injection may reduce site pain intensity 48 hours after injection (low‐quality evidence). We observed no clear differences in bruise size after slow injection compared to fast injection (low‐quality evidence). Results of this review suggest that slow injection may be associated with lower pain intensity 48 hours post injection compared to fast injection. However, new trials with a more robust design and focus on different injection techniques and broader outcomes including haematoma might be useful in strengthening our certainty around these results. In addition, trials are needed to evaluate other aspects that might impact adverse outcomes such as bruising, haematoma, and pain at the injection site, for example, different types of heparin given (unfractionated (UFH) or low molecular weight heparin (LMWH)), needle gauge, drug volume injected, cold applied to the injection site, injection site and injection technique used, and injector role and experience. AcknowledgementsWe would like to thank Cochrane Vascular for extensive and kind support provided, and Dr Saharnaz Nedjat for input into the previous version of this review. AppendicesAppendix 1. CENTRAL search strategySearch run on Mon Mar 20 2017#1MESH DESCRIPTOR Heparin EXPLODE ALL TREES3883#2*heparin*:TI,AB,KY9079#3LMWH:TI,AB,KY847#4(nadroparin* or fraxiparin* or enoxaparin* or Clexane or klexane or lovenox or dalteparin* ):TI,AB,KY2110#5(ardeparin or normiflo or tinzaparin or logiparin or Innohep or certoparin or sandoparin or reviparin or clivarin* or danaproid or danaparoid ):TI,AB,KY371#6(Fragmin or Kabi 2165 or Kabi2165 or FR 860 or FR860):TI,AB,KY209#7(antixarin or ardeparin* or bemiparin* or Zibor or cy 222 or cy222 or embolex or monoembolex or parnaparin* or rd 11885 or tedelparin or Kabi 2165 or Kabi2165 ):TI,AB,KY154#8(emt 966 or emt966 or emt 967 or emt967 or pk 10169 or pk10169):TI,AB,KY8#9(cy 216 or cy216 or seleparin* or tedegliparin or seleparin* or tedegliparin* or tedelparin or calciparin*):TI,AB,KY70#10(kb 101 or kb101 ):TI,AB,KY3#11(lomoparan or orgaran):TI,AB,KY28#12(parnaparin or fluxum or lohepa or lowhepa or parvoparin ):TI,AB,KY34#13(op 2123 or op2123 ):TI,AB,KY1#14(AVE5026 or AVE 5026):TI,AB,KY2#15#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #1410033#16MESH DESCRIPTOR Injections, Subcutaneous EXPLODE ALL TREES3847#17subcutan*:TI,AB,KY16583#18(sc or s.c):TI,AB,KY7296#19#16 OR #17 OR #1819485#20MESH DESCRIPTOR Contusions93#21bruis*:TI,AB,KY486#22contus*:TI,AB,KY537#23indurat*:TI,AB,KY858#24MESH DESCRIPTOR Hematoma402#25haematoma*:TI,AB,KY525#26hematoma*:TI,AB,KY2882#27MESH DESCRIPTOR Pain EXPLODE ALL TREES34252#28pain*:TI,AB,KY94480#29#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28102440#30#15 AND #19 AND #29303#31* NOT SR‐PVD:CC AND 31/08/2013 TO 28/02/2017:DL79662#32#30 AND #3163 Appendix 2. Trials registries searchesClinicalTrials.gov 12 studies found for: heparin AND subcutaneous AND pain 4 studies found for: heparin AND subcutaneous AND bruising World Health Organization International Clinical Trials Registry Platform 5 records for 5 trials found for: heparin AND subcutaneous AND bruising (2 NEW and not NCT) 6 records for 6 trials found for: heparin AND subcutaneous AND pain (2 new not in NCT) ISRCTN Register 3 results subcutaneous AND heparin AND pain (0 new) 1 results subcutaneous AND heparin AND bruising (0 new) Appendix 3. Authors' Iranian search strategy1Heparin AND Subcutaneous AND Injection (title or abstract)12 Appendix 4. Google Scholar search strategy1((heparin OR enoxaparin OR LMWH) AND subcutaneous AND injection AND (duration OR speed) AND (bruising OR pain) AND trial)) ABSTRACT3900 NotesEdited (no change to conclusions) Data and analysesComparison 1Slow versus fast heparin injections Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size1 Intensity of injection pain3Mean Difference (IV, Random, 95% CI)Subtotals only1.1 Immediately after each injection2140Mean Difference (IV, Random, 95% CI)‐1.52 [‐3.56, 0.53]1.2 48 hours after injection259Mean Difference (IV, Random, 95% CI)‐1.68 [‐2.91, ‐0.45]1.3 60 hours after injection140Mean Difference (IV, Random, 95% CI)‐1.0 [‐2.15, 0.15]1.4 72 hours after injection140Mean Difference (IV, Random, 95% CI)‐0.8 [‐1.70, 0.10]2 Bruise size 48 hours after injection4459Std. Mean Difference (IV, Random, 95% CI)‐0.60 [‐1.24, 0.04]2.1 Bruise size (mm2)2140Std. Mean Difference (IV, Random, 95% CI)‐0.30 [‐0.64, 0.03]2.2 Bruise size (mm)2319Std. Mean Difference (IV, Random, 95% CI)‐1.69 [‐5.07, 1.70]3 Bruise size2Mean Difference (IV, Fixed, 95% CI)Subtotals only3.1 60 hours after injection (mm2)140Mean Difference (IV, Fixed, 95% CI)‐3.85 [‐8.99, 1.29]3.2 72 hours after injection (mm2)2140Mean Difference (IV, Fixed, 95% CI)‐2.29 [‐6.57, 1.99] Open in a separate window What's newLast assessed as up‐to‐date: 20 March 2017. DateEventDescription2 October 2017AmendedError in contact details of contact author corrected2 October 2017New citation required but conclusions have not changedError in contact details of contact author corrected HistoryProtocol first published: Issue 4, 2009 Review first published: Issue 7, 2014 DateEventDescription19 September 2017New search has been performedNew search run. Three new studies included and 7 new studies excluded19 September 2017New citation required and conclusions have changedNew search run. Three new studies included and 7 new studies excluded. Text amended to reflect current Cochrane standards. 'Summary of findings' table added. Conclusions changed1 June 2015AmendedError in plain language summary regarding speed of intervention amended Differences between protocol and reviewThe protocol stated that this review would include randomised controlled trials, clinical controlled trials, and quasi‐experimental studies. However, on the basis of discussions with the Vascular Group editorial base, review authors agreed to exclude clinical controlled trials and quasi‐experimental studies to reduce risk of bias. Characteristics of studiesCharacteristics of included studies [ordered by study ID]MethodsDesign: randomised and self‐controlled trialParticipantsBaseline: 150 participants ‐ 102 female and 48 male; mean age of participants was 74.8 (SD 12.37) years MethodsRandomised parallel controlled trialParticipantsBaseline: 60 participants were divided into 3 groups. We reported the results of 20 participants in the 10‐second heparin injection group and 20 participants in the 30‐second heparin injection group ‐ 13 male and 27 female; mean age in the intervention group was 62.7 (SD 8.83) years and in the control group 57.9 (SD 12.5) years. MethodsDesign: randomised self‐controlled trialParticipantsBaseline: 50 participants ‐ 25 male and 25 female; mean age of participants was 55.25 (SD 12.37) years MethodsDesign: RCT, factorial designParticipantsBaseline: 60 participants were divided into 6 groups. We reported the results of 9 participants in the 10‐second heparin injection group and 10 participants in the 30‐second heparin injection group ‐ 13 male and 6 female; mean age in the intervention group was 61.5 (SD 11.5) years and in the control group 61.6 (SD 6.5) years. APTT: activated partial thromboplastin time. CIS: Cochrane Vascular Information Specialist. cm: centimetres. hr: hours. IU: international units. LMWH: low molecular weight heparin. mm: millimetres. RCT: randomised controlled trial. SC: subcutaneous. SD: standard deviation. VAS: visual analogue scale. Characteristics of excluded studies [ordered by study ID]StudyReason for exclusionIntervention: comparing 4 different techniques of heparin injectionQuasi‐experimental designQuasi‐experimental designQuasi‐experimental designParticipants used anticoagulant drugs during the studyQuasi‐randomised designQuasi‐randomised designNon‐random designIntervention: comparing 10‐second heparin injection vs 30‐second heparin injection plus air lockQuasi‐experimental designIntervention: comparing 4 administration techniques of heparin injectionIntervention: comparing 2 administration techniques of heparin injectionNon‐random designIntervention: comparing 4 administration techniques of heparin injection with speeds of less than 20 secondsParticipants used anticoagulant drugs during the studyIntervention: comparing 10‐second injection and waiting for 10 seconds before withdrawal of the needle vs 10‐second injectionQuasi‐experimental designQuasi‐experimental designNon‐random designIntervention: comparing 3 different techniques of heparin injectionIntervention: comparing 2 administration techniques of heparin injection Contributions of authorsMM: design of the review; literature search and identification of trials for inclusion; evaluation of methodological quality of included trials; data extraction; contact with trial authors; interpretation of data; writing of the draft review; and assuming responsibility for writing of future updates. LJ: design of the review; literature search and identification of trials for inclusion; evaluation of methodological quality of included trials; data extraction; interpretation of data; and writing the review. AAS: design of the review; methodological advice; writing of the review; overall supervision. Sources of supportInternal sources
External sources
Declarations of interestMM: none known. LJ: none known. AAS: none known. ReferencesReferences to studies included in this review
References to studies excluded from this review
Additional references
|